HeraMED continues to forge value adding partnerships
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
The good news keeps flowing for medical technology company, HeraMED Limited (ASX:HMD) with the company announcing today that it has entered into an agreement with leading midwife service provider, Kinderheldin GmbH.
This follows news earlier in the week that the company had received FDA clearance for its HeraBEAT foetal heart monitoring device, which built on other promising collaboration agreements with leading healthcare group’s such as Mayo Clinic.
HeraMED is revolutionising the pregnancy experience by empowering personalised, continuous and proactive home monitoring, delivering better care at a lower cost.
Central to developing the group’s new technologies is the development of an extensive database that will provide a bank of information in relation to pregnancy histories as detailed by hospitals and other medical tuitions.
Provision of web-based online midwife services
Under the agreement announced today, HeraMED and Kinderheldin will collaborate to provide Kinderheldin’s web-based online midwife service to expecting mothers using the company’s HeraBEAT smart foetal heart rate monitor.
This will culminate in the inaugural release of HeraBEAT Plus and progresses HeraMED’s ongoing push into telemedicine ahead of the US launch in 2020.
Kinderheldin (www.kinderheldin.de) is a leading midwife service provider based in Berlin.
The group has developed a web based, online platform that offers expecting parents access to large number of midwives through online chat services or telephones.
Kinderheldin’s team of midwives is supported by an experienced medical advisory board which includes top-tier physicians and an in-country software development team.
HeraMED and German distributor Duttenhofer will offer the online service to consumers using the HeraBEAT device via individual access codes, which will be provided when the device has been purchased.
Kinderheldin’s midwives will also be able to access data generated from HeraBEAT, which will assist them in making more informed decisions and providing a better duty of care.
Bringing insurance companies on board
Kinderheldin and HeraMED are also progressing discussions with insurance companies in the Kinderheldin network for use of the device and service.
Kinderheldin works with approximately fifty insurance companies including some of Germany’s oldest and largest.
Its partners include Barmer, BKK Mobil Oil and HEK amongst others.
The group also has co-operation agreements with five major hospitals in the country, and both parties will progress discussions with these hospitals to deploy HeraMED’s solutions.
All parties are working to progress the launch of the solution in time for Duttenhofer’s planned launch of HeraBEAT in Germany, Austria and Switzerland.
Highlighting the competitive advantages that this agreement provides, HeraMED chief executive and co-founder David Groberman said, “This agreement provides HeraMED with a significant differentiator and competitive advantage.
‘’Having a midwifery service that expecting mothers and new parents can access as part of our service offering puts the company leagues ahead as it pushes further into telehealth and connected care.
“Kinderheldin is a tremendous partner for HeraMED as it boasts strong relationships with some of Germany’s oldest and largest insurance companies and hospital groups.
“We look forward to progressing discussions with the top-tier organisations in their network with the aim to implement HeraBEAT and potentially HeraCARE more broadly.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
